Crossref
26-A-15662-ACC TRENDS IN UTILIZATION, SPENDING, AND COVERAGE FOR PCSK9 INHIBITORS IN MEDICARE PART D
JACC · 2026-04 · 87 (13) · A316
DOI: 10.1016/j.jacc.2026.02.783 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC, 2026-04. Verfasst von Jalpa Doshi und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Doshi, J., Klebanoff, M., Merchant, M., Li, P., & Kazi, D. (2026). 26-A-15662-ACC TRENDS IN UTILIZATION, SPENDING, AND COVERAGE FOR PCSK9 INHIBITORS IN MEDICARE PART D. JACC, 87(13), A316. https://doi.org/10.1016/j.jacc.2026.02.783
Vancouver
Doshi J, Klebanoff M, Merchant M, Li P, Kazi D. 26-A-15662-ACC TRENDS IN UTILIZATION, SPENDING, AND COVERAGE FOR PCSK9 INHIBITORS IN MEDICARE PART D. JACC. 2026;87(13):A316. doi:10.1016/j.jacc.2026.02.783
BibTeX
@article{Doshi2026,
author = {Doshi, Jalpa and Klebanoff, Matthew and Merchant, Maya and Li, Pengxiang and Kazi, Dhruv},
title = {26-A-15662-ACC TRENDS IN UTILIZATION, SPENDING, AND COVERAGE FOR PCSK9 INHIBITORS IN MEDICARE PART D},
journal = {JACC},
year = {2026},
volume = {87},
number = {13},
pages = {A316},
doi = {10.1016/j.jacc.2026.02.783}
}
EUVIMED